SCHEMBL1012144

SCHEMBL1012144

CCOC(=O)Nc1cccnn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.53
CTDSP1 Q9GZU7 1/20 0.50
KDM4E B2RXH2 3/20 0.47
GLA P06280 1/20 0.47
POLB P06746 1/20 0.47
CYP1A2 P05177 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 2/20 0.45
ALDH1A1 P00352 4/20 0.44
HPGD P15428 4/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
FFAR2 O15552 1/20 0.44
HSD17B10 Q99714 4/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11776995 0.84 GAA (0.54) KMT2ACTDSP1KDM4EGLAPOLB
SCHEMBL4027480 0.83 KDM4E (0.47) KMT2AKDM4EALDH1A1SMN1; SMN2FFAR2
SCHEMBL27721394 0.81 KMT2A (0.53) KMT2AKDM4EGLAPOLBCYP1A2
SCHEMBL3272690 0.80 FFAR2 (0.41) KMT2ACTDSP1FFAR2GOT1
SCHEMBL6179239 0.79 NPC1 (0.60) KMT2AKDM4EALDH1A1RAB9ANPC1
SCHEMBL29655094 0.79 NPC1 (0.60) KMT2AKDM4EALDH1A1RAB9ANPC1
SCHEMBL4410599 0.78 FFAR2 (0.47) KDM4EPOLBCYP2C19ALDH1A1HPGD
SCHEMBL30071242 0.78 FFAR2 (0.47) KDM4EPOLBCYP2C19ALDH1A1HPGD
SCHEMBL31038470 0.77 NAMPT (0.46) KMT2ARAB9ANPC1FFAR2GOT1
SCHEMBL4093611 0.77 NAMPT (0.46) KMT2ARAB9ANPC1FFAR2GOT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
EP-2076508-A2 BIARYL ETHER UREA COMPOUNDS Pfizer Products Inc. (US) 2009-07-08 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
WO-2008047229-A2 BIARYL ETHER UREA COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC KMT2A 1650/4885CTDSP1 2766/4885KDM4E 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.